The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The current state of serum biomarkers of hepatotoxicity
Abstract
The level of serum alanine aminotransferase (ALT) activity reflects damage to hepatocytes and is considered to be a highly sensitive and fairly specific preclinical and clinical biomarker of hepatotoxicity. However, an increase in serum ALT activity level has also been associated with other organ toxicities, thus, indicating that the enzyme has specificity beyond liver in the absence of correlative histomorphologic alteration in liver. Thus, unidentified non-hepatic sources of serum ALT activity may inadvertently influence the decision of whether to continue development of a novel pharmaceutical compound. To assess the risk of false positives due to extraneous sources of serum ALT activity, additional biomarkers are sought with improved specificity for liver function compared to serum ALT activity alone. Current published biomarker candidates are reviewed herein and compared with ALT performance in preclinical and on occasion, clinical studies. An examination of the current state of hepatotoxic biomarkers indicates that serum F protein, arginase I, and glutathione-S-transferase alpha (GSTalpha) levels, all measured by ELISA, may show utility, however, antibody availability and high cost per run may present limitations to widespread applicability in preclinical safety studies. In contrast, the enzymatic markers sorbitol dehydrogenase, glutamate dehydrogenase, paraxonase, malate dehydrogenase, and purine nucleoside phosphorylase are all readily measured by photometric methods and use reagents that work across preclinical species and humans and are commercially available. The published literature suggests that these markers, once examined collectively in a large qualification study, could provide additional information relative to serum ALT and aspartate aminotransferase (AST) values. Since these biomarkers are found in the serum/plasma of treated humans and rats, they have potential to be utilized as bridging markers to monitor acute drug-induced liver injury in early clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 19,795
Concordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050
The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
Davies, H. G., Richter, R. J., Keifer, M., Broomfield, C. A., Sowalla, J., & Furlong, C. E. (1996) · Nature Genetics · doi:10.1038/ng1196-334 · Cited by 603
A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters
Ramaiah, S. K. (2007) · Food and Chemical Toxicology · doi:10.1016/j.fct.2007.06.007 · Cited by 494
Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., & Seeff, L. B. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.12.2050 · Cited by 439
Serum alanine aminotransferase in skeletal muscle diseases†
Nathwani, R. A., Pais, S., Reynolds, T. B., & Kaplowitz, N. (2005) · Hepatology · doi:10.1002/hep.20548 · Cited by 398
Zollner, G., Marschall, H.-U., Wagner, M., & Trauner, M. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060010s · Cited by 335
Determination of paraoxonase (PON1) status requires more than genotyping
Richter, R. J., & Furlong, C. E. (1999) · Pharmacogenetics · doi:10.1097/00008571-199912000-00009 · Cited by 281
Costa, L. G., Cole, T. B., Jarvik, G. P., & Furlong, C. E. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152421 · Cited by 264
Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response
Feingold, K. R., Memon, R. A., Moser, A. H., & Grunfeld, C. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00084-7 · Cited by 248
Serum Transaminase Elevations as Indicators of Hepatic Injury Following the Administration of Drugs
Amacher, D. E. (1998) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1998.1201 · Cited by 247
Boone, L., Meyer, D., Cusick, P., Ennulat, D., Bolliger, A. P., Everds, N., Meador, V., Elliott, G., Honor, D., Bounous, D., et al. (2005) · Veterinary Clinical Pathology · doi:10.1111/j.1939-165x.2005.tb00041.x · Cited by 232
Coles, B. F., Morel, F., Rauch, C., Huber, W. W., Yang, M., Teitel, C. H., Green, B., Lang, N. P., & Kadlubar, F. F. (2001) · Pharmacogenetics · doi:10.1097/00008571-200111000-00004 · Cited by 225
Xu, J. J., Diaz, D., & O’Brien, P. J. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.09.011 · Cited by 224
Costa, L. G., Cole, T. B., Vitalone, A., & Furlong, C. E. (2005) · Clinica Chimica Acta · doi:10.1016/j.cccn.2004.09.019 · Cited by 217
Polymorphisms in the human paraoxonase (PON1) promoter
Brophy, V. H., Hastings, M. D., Clendenning, J. B., Richter, R. J., Jarvik, G. P., & Furlong, C. E. (2001) · Pharmacogenetics · doi:10.1097/00008571-200102000-00009 · Cited by 181
Coles, B. F., & Kadlubar, F. F. (2005) · Methods in Enzymology · doi:10.1016/s0076-6879(05)01002-5 · Cited by 171
Ng, C. J., Bourquard, N., Grijalva, V., Hama, S., Shih, D. M., Navab, M., Fogelman, A. M., Lusis, A. J., Young, S., & Reddy, S. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605379200 · Cited by 165
Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats
O'Brien, P. J., Slaughter, M. R., Polley, S. R., & Kramer, K. (2002) · Laboratory Animals · doi:10.1258/002367702320162414 · Cited by 152
Structural, Functional, and Clinical Aspects of γ-Glutamyltransferase
Goldberg, D. M. (1980) · CRC Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408368009108725 · Cited by 149
Tong, V., Teng, X. W., Chang, T. K. H., & Abbott, F. S. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi185 · Cited by 148
Rozenberg, O., Shih, D. M., & Aviram, M. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.12.030 · Cited by 147
Yang, R., Blaileanu, G., HANSEN, B. C., Shuldiner, A. R., & Gong, D. (2002) · Genomics · doi:10.1006/geno.2002.6722 · Cited by 134
Rodrigo, L. S., Hernández, A. F., López-Caballero, J. J., Gil, F., & Pla, A. (2001) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(01)00225-3 · Cited by 125
Giffen, P. S., Turton, J. A., Andrews, C. M., Barrett, P., Clarke, C. J., Fung, K.-W., Munday, M. R., Roman, I., Smyth, R., Walshe, K., et al. (2003) · Archives of Toxicology · doi:10.1007/s00204-003-0458-7 · Cited by 112
Lindblom, P., Rafter, I., Copley, C. G., Andersson, U., Hedberg, J. J., Berg, A., Samuelsson, A., Hellmold, H., Cotgreave, I. A., & Glinghammar, B. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.07.023 · Cited by 107
Geuken, E., Visser, D. S., Kuipers, F., Blokzijl, H., Leuvenink, H. G. D., de Jong, K. P., Peeters, P. M. J. G., Jansen, P. L. M., Slooff, M. J. H., Gouw, A. S. H., et al. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.023 · Cited by 105
Sensitivity of several serum enzymes in detecting carbon tetrachloride-induced liver damage in rats
Korsrud, G. O., Grice, H. C., & McLaughlan, J. M. (1972) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(72)90255-4 · Cited by 97
Amacher, D. E., Adler, R. R., Herath, A., & Townsend, R. R. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2005.049908 · Cited by 92
Review of Hemoglobin-Induced Myocardial Lesions
Burhop, K. E., Gordon, D. E., & Estep, T. N. (2004) · Artificial Cells Blood Substitutes and Biotechnology · doi:10.1081/bio-200027429 · Cited by 80
Serum gamma glutamyl transferase as a specific indicator of bile duct lesions in the rat liver.
Leonard, T. B., Neptun, D. A., & Popp, J. A. (1984) · PubMed · Cited by 76
Beckett, G. J., Foster, G. R., Hussey, A. J., Oliveira, D. B. G., Donovan, J. W., Prescott, L. F., & Proudfoot, A. T. (1989) · Clinical Chemistry · doi:10.1093/clinchem/35.11.2186 · Cited by 69
A Proteomic Investigation of Drug-Induced Steatosis in Rat Liver
Meneses‐Lorente, G., Guest, P. C., Lawrence, J. W., Muniappa, N., Knowles, M. R., Skynner, H. A., Salim, K., Cristea, I. M., Mortishire‐Smith, R. J., Gaskell, S. J., et al. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034203n · Cited by 57
Rozek, L. S., Hatsukami, T. S., Richter, R. J., Ranchalis, J., Nakayama, K. S., McKinstry, L. A., Gortner, D. A., Boyko, E. J., Schellenberg, G. D., Furlong, C. E., et al. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400489-jlr200 · Cited by 56
Pharmacogenomic Considerations of The Paraoxonase Polymorphisms
Furlong, C. E., Cole, T. B., Jarvik, G. P., & Costa, L. G. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.3.341 · Cited by 50
Risperidone- and Quetiapine-Induced Cholestasis
Wright, T. M., & VandenBerg, A. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k145 · Cited by 48
Murayama, H., Ikemoto, M., Fukuda, Y., Tsunekawa, S., & Nagata, A. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.06.018 · Cited by 36
Neve, S., Aarenstrup, L., Tornehave, D., Rahbek-Nielsen, H., Corydon, T. J., Roepstorff, P., & Kristiansen, K. (2003) · Cell Biology International · doi:10.1016/s1065-6995(03)00117-3 · Cited by 28
Diagnosis and treatment of primary biliary cirrhosis.
Nishio, A., Keeffe, E. B., Ishibashi, H., & Gershwin, M. E. (2000) · PubMed · Cited by 28
Evaluating Toxin-induced Hepatic Injury in Rats by Laboratory Results and Discriminant Analysis
Carakostas, M. C., Gossett, K. A., CHURCH, G. E., & Cleghorn, B. (1986) · Veterinary Pathology · doi:10.1177/030098588602300306 · Cited by 26
FUKUDA, M., Yokoyama, H., Mizukami, T., Ohgo, H., Okamura, Y., Kamegaya, Y., Horie, Y., Kato, S., & Ishii, H. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03408.x · Cited by 24
Stability of Sorbitol Dehydrogenase Activity in Bovine and Equine Sera
Horney, B. S., Honor, D. J., MacKenzie, A., & Burton, S. A. (1993) · Veterinary Clinical Pathology · doi:10.1111/j.1939-165x.1993.tb00869.x · Cited by 21
Cited by
Circulating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Biochemical markers of muscular damage
Brancaccio, P., Lippi, G., & Maffulli, N. (2010) · cclm · doi:10.1515/cclm.2010.179 · Cited by 839
Plasma MicroRNA-122 as a Biomarker for Viral-, Alcohol-, and Chemical-Related Hepatic Diseases
Zhang, Y., Jia, Y., Zheng, R., Guo, Y., Wang, Y., Guo, H., Fei, M., & Sun, S. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.147850 · Cited by 415
Current Developments in Salivary Diagnostics
Miller, C. S., Foley, J. D., Bailey, A. L., Campell, C. L., Humphries, R. L., Christodoulides, N., Floriano, P. N., Simmons, G., Bhagwandin, B., Jacobson, J. W., et al. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.68 · Cited by 389
Metadata
- Authors
- Ozer, J., Ratner, M., Shaw, M., Bailey, W., & Schomaker, S.
- Venue
- Toxicology
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 245
- Issue
- 3
- Pages
- 194-205
- ISSN
- 0300-483X (ISSN-L)
- OpenAlex
- W2047718984
- Cited by
- 1,269
- References
- 42
- FWCI
- 23.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.